Aytu biopharma reports fiscal 2024 first quarter financial results

Q1 2024 adjusted ebitda of $2.2 million rx segment net revenue of $17.8 million and adjusted ebitda of $2.4 million in q1 2024 q1 2024 adhd net revenue up 31% compared to q1 2023 $20.0 million cash balance at september 30, 2023 company to host conference call today at 4:30pm et denver, co / accesswire / november 14, 2023 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the first quarter of fiscal 2024 ended september 30, 2023. q1 2024 commercial highlights (3 months ending september 30, 2023) total net revenue was $22.1 million, compared to $27.7 million.
AYTU Ratings Summary
AYTU Quant Ranking